Source MDx
ONCOLOGY AUTOIMMUNE DISEASES INFECTIOUS DISEASES CARDIOVASCULAR DISEASES OTHER DISEASES
Pipeline of Molecular
Diagnostic Tests
Prostate Cancer
Lung Cancer
About Source MDx
Technology
Patents
News and Downloads
Contact Us

Patents

Source MDx® holds a broad-based, array of 26 issued patents in 22 countries and an additional 74 pending patent applications worldwide that cover technical aspects of RNA transcript-based measurement, concepts surrounding normal ranges in healthy human subjects, disease specific Precision Profiles™ and statistical methods generating multi-gene models that discriminate disease subjects from normal subjects. Source MDx®'s patent portfolio places the company in a highly differentiated position in the realm of molecular diagnostics, particularly as it relates to inflammation and immune related diseases and cancer. As such, Source MDx® continues to be at the forefront of researching and understanding the link between cancer and the immune response and how this link can be translated into whole blood RNA transcript-based diagnostic tests.

Core to Source MDx®'s intellectual property portfolio is a patent on the use of two or more RNA transcripts (target genes) amplified for use in a molecular diagnostic. Optimized RNA transcript-based measurement, with target genes designed to meet criteria of matched amplification efficiencies (concept of calibration) enables meaningful comparisons of gene expression responses in a variety of pre-clinical and clinical settings.

The value of the company's portfolio is enhanced by the inclusion of patent grants in 22 countries including leading industrial nations in North America, Europe and Asia. A brief summary of the patent portfolio includes ten groups of patents described below. The first three groups of patents are foundational molecular medicine patents that include issued patents in 22 countries, as well as pending international patents. The fourth group of patents focuses on cancer specific biomarker panels for seven types of cancer. The fifth group focuses on specific prostate cancer biomarker panels for early detection and predicting survival. The sixth group includes melanoma specific biomarker panels for predicting survival. The seventh grouping includes specific biomarker panels for five types of autoimmune diseases. The eighth group includes specific biomarker panels for infectious diseases including sepsis. The ninth group includes specific biomarker panels for other inflammatory diseases including eye disease. The tenth group includes all other patents.

  1. The use of quantitative real-time PCR that has been optimized for precision and calibration in the measurement of RNA transcripts. This enables the detection of more subtle changes in gene expression that may be indicative of a disease state.

    Issued Patents
    Patent NumberCountry Issue/Grant Date Earliest Priority Date Date
    6,692,916U.S.February 17, 2004June 28, 1999
    784233AustraliaJune 22, 2006June 28, 1999
    85924SingaporeJune 30, 2006June 28, 1999
    *1198585AustriaJune 13, 2007June 28, 1999
    *1198585BelgiumJune 13, 2007 June 28, 1999
    *1198585 Cyprus June 13, 2007 June 28, 1999
    *1198585DenmarkJune 13, 2007 June 28, 1999
    *1198585 Finland June 13, 2007 June 28, 1999
    *1198585 France June 13, 2007 June 28, 1999
    *1198585 Germany June 13, 2007 June 28, 1999
    *1198585 Greece June 13, 2007 June 28, 1999
    *1198585 Ireland June 13, 2007 June 28, 1999
    *1198585 Italy June 13, 2007 June 28, 1999
    *1198585LuxembourgJune 13, 2007 June 28, 1999
    *1198585 Monaco June 13, 2007 June 28, 1999
    *1198585 Netherlands June 13, 2007 June 28, 1999
    *1198585 Portugal June 13, 2007 June 28, 1999
    *1198585 Spain June 13, 2007 June 28, 1999
    *1198585 Sweden June 13, 2007 June 28, 1999
    *1198585SwitzerlandJune 13, 2007 June 28, 1999
    *1198585 United Kingdom June 13, 2007 June 28, 1999

    * European Patent No. 1198585 has been opposed by two parties. The Oppositions are currently under examination by the European Patent Office.

    Pending Patent Applications
    Application NumberCountryFiling Date
    10/703143U.S.November 3, 2003
    10/701391U.S.November 3, 2003
    2378008CanadaJune 28, 2000
    147349IsraelJune 28, 2000
    2001-528624JapanJune 28, 2000

  2. The concept of normal gene expression ranges in healthy human subjects and the use of a healthy normal human reference dataset for applying "treat-to-normal" strategies in the detection of disease and the evaluation of therapeutic response. Optimized RNA transcript-based measurement coupled with established normal reference ranges is the foundation of Source MDx®’s Precision Profile™ molecular diagnostic system. This brings RNA transcript-based measurement to the level of blood chemistries where measurements such as glucose levels are routinely compared to established normal ranges in order to facilitate medical decisions. Also claims the use of two or more genes in an RNA-based diagnostic using whole blood or any other biofluid or tissue sample to indicate an inflammatory or immune response. Such responses can signal the presence of disease, and in cancer, may further indicate the presence of tumors.

    Issued Patents
    Patent Number Country Issue/Grant Date Earliest Priority Date Date
    6,960,439U.S.November 1, 2005 June 28, 1999

  3. Information technology and statistical methods regarding multi-gene algorithms that translate molecular data into actionable medical information regarding presence or progression of disease and response to therapy in individuals.

    Issued Patents
    Patent Number Country Issue/Grant Date Earliest Priority Date Date
    *6,964,850 U.S. November 15, 2005 November 9, 2001
    227975 India January 27, 2009 November 9, 2001

    * A Request for Ex Parte Re-Examination has been filed against U.S. Patent No. 6,964,850. The Re-examination is currently being reviewed by the United States Patent and Trademark Office.

    Pending Patent Applications
    Application NumberCountryFiling Date
    11/158504U.S.June 22, 2005
    11/159376U.S.June 22, 2005
    2466502CanadaNovember 8, 2002
    02826908.XChinaNovember 8, 2002
    02792239.2EuropeNovember 8, 2002
    2003-542649JapanNovember 8, 2002
    04-7007103KoreaNovember 8, 2002

  4. Cancer specific biomarker panels (Precision Profiles™) including melanoma, colon, breast, prostate, cervical, ovarian and lung cancer.

    Pending Patent Applications
    IndicationApplication NumberCountryFiling Date
    Melanoma Not yet assigned U.S. November 6, 2007
    Melanoma 2007328427 Australia November 6, 2007
    Melanoma Not yet assigned Canada November 6, 2007
    Melanoma 07870851.8 Europe November 6, 2007
    Lung 12/514,686 U.S. November 6, 2007
    Lung 2007322206 Australia November 6, 2007
    Lung Not yet assigned Canada November 6, 2007
    Lung 07861766.9 Europe November 6, 2007
    Colon 12/514775 U.S. November 6, 2007
    Colon 2007322207 Australia November 6, 2007
    Colon Not yet assigned Canada November 6, 2007
    Colon 07861767.7 Europe November 6, 2007
    Prostate PCT/US2007/023425 PCT November 6, 2007
    Ovarian PCT/US2007/023384 PCT November 6, 2007
    Breast PCT/US2007/023385 PCT November 6, 2007
    Cervical PCT/US2007/023387 PCT November 6, 2007
    Cancer General PCT/US2007/023459 PCT November 6, 2007

  5. Prostate cancer specific biomarker panels (Precision Profiles™) for early cancer detection and predicting cancer survival.

    Pending Patent Applications
    Indication Application Number Country Filing Date
    Prostate Cancer-Early Detection 61/142789 U.S. January 6, 2009
    Prostate Cancer-Early Detection 61/150666 U.S. February 6, 2009
    Prostate Cancer-Early Detection 61/163354 U.S. March 25, 2009
    Prostate Cancer-Early Detection 61/170017 U.S. April 16, 2009
    Prostate Cancer-Early Detection 61/178342 U.S. May 14, 2009
    Prostate Cancer-Survival PCT/US2009/049935 PCT July 8, 2009

  6. Melanoma specific biomarker panels (Precision Profiles™) for predicting cancer survival.

    Pending Patent Applications
    Indication Application Number Country Filing Date
    Melanoma-Survival 61/110786 U.S. November 3, 2008

  7. Disease specific biomarker panels (Precision Profiles™) in autoimmune including rheumatoid arthritis, multiple sclerosis, transplant rejection and immunosuppression.

    Pending Patent Applications
    IndicationApplication NumberCountryFiling Date
    Rheumatoid Arthritis11/529010U.S.September 27, 2006
    Rheumatoid Arthritis2006294477AustraliaSeptember 27, 2006
    Rheumatoid Arthritis2624359CanadaSeptember 27, 2006
    Rheumatoid Arthritis06836158.3EuropeSeptember 27, 2006
    Multiple Sclerosis11/155930U.S.June 16, 2005
    Multiple Sclerosis11/454553U.S.June 16, 2006
    Multiple Sclerosis2006259306AustraliaJune 16, 2006
    Multiple Sclerosis2612492CanadaJune 16, 2006
    Multiple Sclerosis09154300.9EuropeJune 16, 2006
    Multiple Sclerosis11/827892U.S.July 13, 2007
    Multiple Sclerosis 2007272824 Australia July 13, 2007
    Multiple Sclerosis 2658171 Canada July 13, 2007
    Multiple Sclerosis 07810433.8 Europe July 13, 2007
    Transplant Rejection11/897160U.S.August 28, 2007
    Transplant Rejection 2661487 Canada August 28, 2007
    Transplant Rejection 07837480.8 Europe August 28, 2007
    Lupus 12/524677 U.S. January 25, 2008
    Lupus 2008209462 Australia January 25, 2008
    Lupus Not yet assigned Canada January 25, 2008
    Lupus 08724851.4 Europe January 25, 2008
    OsteoarthritisPCT/US2009/048684PCTJune 25, 2009

  8. Disease specific biomarker panels (Precision Profiles™) in infectious disease including sepsis.

    Issued Patents
    Patent Number Country Issue/Grant Date Earliest Priority Date Date
    234094 India May 5, 2009 December 19, 2002

    Pending Patent Applications
    Application NumberCountryFiling Date
    10/742458U.S.December 19, 2003
    2003303238AustraliaDecember 19, 2003
    PI0317612-6BrazilDecember 19, 2003
    2511237CanadaDecember 19, 2003
    200380109850ChinaDecember 19, 2003
    03808491.9EuropeDecember 19, 2003
    3792/CHENP/20IndiaDecember 19, 2003
    2004-562300JapanDecember 19, 2003
    2005/006804MexicoDecember 19, 2003

  9. Disease specific biomarker panels (Precision Profiles™) in other inflammatory diseases including eye diseases.

    Pending Patent Applications
    IndicationApplication NumberCountryFiling Date
    Ocular 12/520675 U.S. December 18, 2007
    Ocular 2007339334 Australia December 18, 2007
    Ocular Not yet assigned Canada December 18, 2007
    Ocular 07863065.4 Europe December 18, 2007

  10. Other patents.

    Issued Patents
    Patent NumberCountryIssue/Grant Date
    7,074,586U.S.July 11, 2006

    Pending Patent Applications
    Application NumberCountryFiling Date
    11/804175U.S.May 16, 2007
    2007254206 Australia May 16, 2007
    2652239 Canada May 16, 2007
    07795008.7 Europe May 16, 2007

© 2009 Source Precision Medicine, Source MDx — Site Map